메뉴 건너뛰기




Volumn 64, Issue 2, 2009, Pages 218-222

Using HIV resistance tests in clinical practice

Author keywords

Genotype; Genotypic resistance testing; Human immunodeficiency virus

Indexed keywords

INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

EID: 67650735812     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp205     Document Type: Editorial
Times cited : (10)

References (11)
  • 1
    • 40049097826 scopus 로고    scopus 로고
    • What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?
    • Grover D, Copas A, Green H et al. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother 2008; 61: 705-13.
    • (2008) J Antimicrob Chemother , vol.61 , pp. 705-713
    • Grover, D.1    Copas, A.2    Green, H.3
  • 2
    • 67650746282 scopus 로고    scopus 로고
    • UK HIV Drug Resistance Database. www.ctu.mrc.ac.uk/hivrdb (10 May 2009, date last accessed).
    • UK HIV Drug Resistance Database. www.ctu.mrc.ac.uk/hivrdb (10 May 2009, date last accessed).
  • 6
    • 27444442983 scopus 로고    scopus 로고
    • Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
    • Sax PE, Islam R, Walensky RP et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316-23.
    • (2005) Clin Infect Dis , vol.41 , pp. 1316-1323
    • Sax, P.E.1    Islam, R.2    Walensky, R.P.3
  • 7
    • 0036149707 scopus 로고    scopus 로고
    • Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection
    • Brenner BG, Routy JP, Petrella M et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76: 1753-61.
    • (2002) J Virol , vol.76 , pp. 1753-1761
    • Brenner, B.G.1    Routy, J.P.2    Petrella, M.3
  • 8
    • 10644238065 scopus 로고    scopus 로고
    • Long-term persistence of primary genotypic resistance after HIV-1 seroconversion
    • Pao D, Andrady U, Clarke J et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37: 1570-3.
    • (2004) J Acquir Immune Defic Syndr , vol.37 , pp. 1570-1573
    • Pao, D.1    Andrady, U.2    Clarke, J.3
  • 9
    • 43949110248 scopus 로고    scopus 로고
    • Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection
    • Little SJ, Frost SDW, Wong JK et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82: 5510-8.
    • (2008) J Virol , vol.82 , pp. 5510-5518
    • Little, S.J.1    Frost, S.D.W.2    Wong, J.K.3
  • 10
    • 0033385403 scopus 로고    scopus 로고
    • Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
    • Devereux HL, Youle M, Johnson MA et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123-7.
    • (1999) AIDS , vol.13
    • Devereux, H.L.1    Youle, M.2    Johnson, M.A.3
  • 11
    • 9144226187 scopus 로고    scopus 로고
    • Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    • Wirden M, Delaugerre C, Marcelin AG et al. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 2004; 48: 644-7.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 644-647
    • Wirden, M.1    Delaugerre, C.2    Marcelin, A.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.